Public access to protocols of contemporary cancer randomized clinical trials

Access to randomized clinical trial (RCT) protocols is necessary for the interpretation and reproducibility of the study results, but protocol availability has been lacking. We determined the prevalence of protocol availability for all published cancer RCTs in January 2020. We found that only 36.1%...

Descripción completa

Detalles Bibliográficos
Autores principales: Babu, Christopher, Mell, Loren, Lee, Nancy, Zakeri, Kaveh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237482/
https://www.ncbi.nlm.nih.gov/pubmed/34176506
http://dx.doi.org/10.1186/s13063-021-05382-7
_version_ 1783714737872175104
author Babu, Christopher
Mell, Loren
Lee, Nancy
Zakeri, Kaveh
author_facet Babu, Christopher
Mell, Loren
Lee, Nancy
Zakeri, Kaveh
author_sort Babu, Christopher
collection PubMed
description Access to randomized clinical trial (RCT) protocols is necessary for the interpretation and reproducibility of the study results, but protocol availability has been lacking. We determined the prevalence of protocol availability for all published cancer RCTs in January 2020. We found that only 36.1% (48/133) of RCTs had an accessible protocol and only 11.3% of RCTs (15/133) had a publicly accessible protocol that was not behind a paywall. Only 18.0% (24/133) of RCTs were published in conjunction with the protocol on the journal website. In conclusion, few cancer RCTs have an accessible research protocol. Journals should require publication of RCT protocols along with manuscripts to improve research transparency. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05382-7.
format Online
Article
Text
id pubmed-8237482
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82374822021-06-29 Public access to protocols of contemporary cancer randomized clinical trials Babu, Christopher Mell, Loren Lee, Nancy Zakeri, Kaveh Trials Letter Access to randomized clinical trial (RCT) protocols is necessary for the interpretation and reproducibility of the study results, but protocol availability has been lacking. We determined the prevalence of protocol availability for all published cancer RCTs in January 2020. We found that only 36.1% (48/133) of RCTs had an accessible protocol and only 11.3% of RCTs (15/133) had a publicly accessible protocol that was not behind a paywall. Only 18.0% (24/133) of RCTs were published in conjunction with the protocol on the journal website. In conclusion, few cancer RCTs have an accessible research protocol. Journals should require publication of RCT protocols along with manuscripts to improve research transparency. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05382-7. BioMed Central 2021-06-27 /pmc/articles/PMC8237482/ /pubmed/34176506 http://dx.doi.org/10.1186/s13063-021-05382-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter
Babu, Christopher
Mell, Loren
Lee, Nancy
Zakeri, Kaveh
Public access to protocols of contemporary cancer randomized clinical trials
title Public access to protocols of contemporary cancer randomized clinical trials
title_full Public access to protocols of contemporary cancer randomized clinical trials
title_fullStr Public access to protocols of contemporary cancer randomized clinical trials
title_full_unstemmed Public access to protocols of contemporary cancer randomized clinical trials
title_short Public access to protocols of contemporary cancer randomized clinical trials
title_sort public access to protocols of contemporary cancer randomized clinical trials
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237482/
https://www.ncbi.nlm.nih.gov/pubmed/34176506
http://dx.doi.org/10.1186/s13063-021-05382-7
work_keys_str_mv AT babuchristopher publicaccesstoprotocolsofcontemporarycancerrandomizedclinicaltrials
AT mellloren publicaccesstoprotocolsofcontemporarycancerrandomizedclinicaltrials
AT leenancy publicaccesstoprotocolsofcontemporarycancerrandomizedclinicaltrials
AT zakerikaveh publicaccesstoprotocolsofcontemporarycancerrandomizedclinicaltrials

Ejemplares similares